Table 2

Overall number of events, rates per 10 000 person years, crude and adjusted hazard ratios for coeliac cohort compared with control cohort (reference group)

OverallFirst year of follow up after diagnosisFollow up beyond year after diagnosis
Condition and cohortNo of participants*Hazard ratio (95% CI)Adjusted hazard ratio (95% CI)No of eventsRate/10 000 yearsAdjusted hazard ratio (95% CI)No of eventsRate/10 000 yearsAdjusted hazard ratio (95% CI)
Any malignancy:*
Control23 4331111152.7139556.51
Coeliac disease46951.29 (1.06 to 1.55)1.31 (1.08 to 1.59)44104.22.07 (1.45 to 2.96)8762.21.10 (0.87 to 1.39)
Gastrointestinal cancer:
Control23 60511146.61649.01.00
Coeliac disease47241.85 (1.22 to 2.81)1.95 (1.27 to 3.00)921.13.31 (1.40 to 7.83)2014.11.65 (0.99 to 2.76)
Breast cancer:
Control23 562112411.318712.31
Coeliac disease47250.35 (0.17 to 0.72)0.31 (0.15 to 0.63)37.00.60 (0.18 to 2.04)53.50.24 (0.10 to 0.60)
Lung cancer:
Control23 61611146.61436.01
Coeliac disease47280.34 (0.13 to 0.95)0.37 (0.13 to 1.02)12.30.40 (0.05 to 3.09)32.10.37 (0.11 to 1.20)
Lymphoproliferative disease:
Control23 6121162.81172.41
Coeliac disease47244.80 (2.71 to 8.50)4.27 (2.36 to 7.74)1125.87.32 (2.65 to 20.24)128.43.40 (1.58 to 7.34)
Prostate cancer:
Control23 6141141.91253.51
Coeliac disease47300.99 (0.41 to 2.38)1.05 (0.42 to 2.57)12.31.30 (0.14 to 12.19)53.51.03 (0.38 to 2.76)
Mortality:
Control23 6091118486.7169798.01
Coeliac disease47281.31 (1.13 to 1.51)1.39 (1.20 to 1.61)73171.02.09 (1.59 to 2.76)163114.61.23 (1.04 to 1.47)
  • * Number vary as participants with event on same date or before start of follow up were excluded.

  • † Adjusted for age, sex, body mass index, and smoking status.